Search

574 Result(s)
Sort by

Innovation from within

Innovation from within

Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.
Benefits & Rewards

Benefits & Rewards

We invest in our people so they will stay and grow with us. We offer benefits such as rewards and development opportunities to help retain employees.
Uncommon_Mutations_Database

Uncommon_Mutations_Database

New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
Boehringer acquires T3 Pharma

Boehringer acquires T3 Pharma

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Dominik Huber

Dominik Huber

Dominik Huber, Our Head of Upstream Manufacturing in Vienna, Dominik Huber, has built his entire, senior-level career with Boehringer Ingelheim.
Boehringer Ingelheim acquires Nerio Therapeutics

Boehringer Ingelheim acquires Nerio Therapeutics

Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
Who are we?

Who are we?

Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Our people

Our people

Ambition. Passion. Integrity. Commitment. Empathy. Individuality. We expect these qualities at all levels.
opening-solids-launch-fabrik

opening-solids-launch-fabrik

Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.